Caligan Partners

What Caligan Partners does

Caligan Partners LP is a New York-based, healthcare-focused private investment firm founded in 2018 that operates as a sector-specialist hedge fund and activist investor in the biotechnology and pharmaceutical industries. The firm, led by Managing Partner David Johnson, concentrates capital in clinical-stage and commercial-stage biotech companies, executing a strategy that combines public equity stakes, private placements, PIPE financings, and board-level activism. Its portfolio activity spans a wide range of therapeutic areas including oncology, rare disease, autoimmune disease, central nervous system disorders, pulmonary disease, and type 1 diabetes, with notable positions in Liquidia Corp (8.1M+ shares; Johnson holds a board seat), Opus Genetics (8.5% beneficial ownership), Verrica Pharmaceuticals, Vor Bio, Cellectar Biosciences, Artiva Biotherapeutics, Sagimet Biosciences, Obsidian Therapeutics, and Diamyd Medical.

The firm's investment approach emphasizes concentrated, high-conviction positions and operational influence, with Johnson holding board seats at Liquidia, Exelixis, and Verrica. Caligan has backed structurally significant transactions including the $350 million Galera/Obsidian reverse merger and the $150 million Vor Bio private placement that installed a new chairman and CEO. The firm generated a 92% return in 2025, attributed to a surge in large-cap pharma M&A and the strongest biotech sector rally since 2014, outperforming comparable specialist Perceptive Advisors (75%).

Caligan's business model relies on management and performance fees from its limited partners in exchange for concentrated healthcare sector exposure. Distribution is conducted through direct institutional LP relationships and high-profile investor conferences such as the Best Ideas Conference. The firm maintains a single headquarters in Midtown Manhattan (780 Third Avenue, 30th Floor) and has expanded its disclosed investment universe into European markets (Sweden via Diamyd Medical). The company does not offer technology products, software, or services, and maintains no public revenue disclosures consistent with its private partnership structure.

Name

Caligan Partners

Legal name

Caligan Partners LP

Website

https://caliganpartners.com

Company type

Private

Founded year

2018

Operating status

Operating

Short description

Caligan Partners LP is a New York-based, healthcare-focused private investment firm founded in 2018 that operates as a specialist hedge fund and activist investor in biotechnology and pharmaceutical companies, generating returns for institutional limited partners through concentrated public equity positions, private placements, and board-level activism.

Ownership category

akta.pro rank

Product category

Healthcare-focused Hedge Fund / Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Healthcare investment management
• Biotech private placements
• Activist hedge fund
• Pharmaceutical equity investing
• Specialist healthcare fund

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Marketing channels2 records

Core offering

Caligan Partners LP is a healthcare-focused private investment firm that manages concentrated investment portfolios in the biotech and pharmaceutical sectors. The firm deploys capital through public equity positions, private placements, PIPE financings, and activist investing strategies targeting undervalued biotechnology companies, and seeks board representation in portfolio companies.

Product overview

Caligan Partners LP is a healthcare-focused investment firm and hedge fund that manages investment portfolios in the biotech/pharmaceutical sector. The firm does not offer technology products or software services; its core business is investment management, including public equity investments, private placements, and activist investing strategies in biotechnology companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare-Focused Investment Management Concentrated, specialist investment management services focused on the healthcare and biotech sectors, offered to institutional limited partners and other qualified investors.
• Biotech Private Placements and PIPE Financings
• Activist Equity Investing in Public Biotechs Activist investment approach in publicly traded biotech companies, frequently taking meaningful ownership stakes (e.g., 8.1 million+ shares in Liquidia; 19.2% stake announced in 2021) and securing board representation for the Managing Partner.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Perceptive Advisors: Healthcare/biotech-focused hedge fund that achieved 75% returns in 2025. Direct comparable to Caligan in sector focus, activist posture, and life-sciences investment strategy.
• Baker Bros. Advisors: Biotech-focused long-only / hedge fund manager that invests across public and private healthcare equities. Comparable in vertical specialization and clinical-asset underwriting.
• OrbiMed: Healthcare-dedicated investment firm spanning venture, growth, and credit. Comparable in cross-cap healthcare investing and biotech specialist underwriting.
• RA Capital Management: Healthcare-focused crossover fund investing in public and private biotech. Repeat co-investor with Caligan in offerings like Artiva and Diamyd.
• EcoR1 Capital: Biotech-focused investment manager that invests across public equities and private financings. Closely comparable in sector focus and PIPE participation.
• Nantahala Capital Management: Hedge fund with a strong biotech focus that has co-led deals with Caligan (e.g., Cellectar $140M, Obsidian $350M). Comparable in small-cap biotech specialization.
• Farallon Capital Management: Multi-strategy hedge fund with a meaningful healthcare sleeve, including activist positions (e.g., Exelixis). Repeat co-investor with Caligan in deals such as Sagimet.
• Deep Track Capital: Biotech-focused hedge fund that invests in PIPEs and private placements. Co-investor with Caligan in the LB Pharmaceuticals financing.
• Vivo Capital: Healthcare-focused investment firm with public and private biotech exposure. Co-investor with Caligan in the Diamyd Medical financing.

Broad incumbents

• Balyasny Asset Management: Large multi-strategy hedge fund with a dedicated healthcare/biotech sleeve. Repeat co-investor with Caligan in Sagimet, Cellectar, Obsidian, and LB Pharmaceuticals financings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/caligan-partners-lp

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Caligan Partners